These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8825123)

  • 1. The significance of heregulin in breast cancer tumor progression and drug resistance.
    Lupu R; Cardillo M; Cho C; Harris L; Hijazi M; Perez C; Rosenberg K; Yang D; Tang C
    Breast Cancer Res Treat; 1996; 38(1):57-66. PubMed ID: 8825123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin].
    Staebler A; Sommers C; Mueller SC; Byers S; Thompson EW; Lupu R
    Breast Cancer Res Treat; 1994; 31(2-3):175-82. PubMed ID: 7881097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.
    Tang CK; Perez C; Grunt T; Waibel C; Cho C; Lupu R
    Cancer Res; 1996 Jul; 56(14):3350-8. PubMed ID: 8764133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer.
    Lupu R; Lippman ME
    Breast Cancer Res Treat; 1993; 27(1-2):83-93. PubMed ID: 7903175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3.
    Chan SD; Antoniucci DM; Fok KS; Alajoki ML; Harkins RN; Thompson SA; Wada HG
    J Biol Chem; 1995 Sep; 270(38):22608-13. PubMed ID: 7673253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
    Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
    Grunt TW; Saceda M; Martin MB; Lupu R; Dittrich E; Krupitza G; Harant H; Huber H; Dittrich C
    Int J Cancer; 1995 Nov; 63(4):560-7. PubMed ID: 7591267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells.
    Cardillo M; Yankelevich B; Mazumder A; Lupu R
    Cancer Immunol Immunother; 1996 Sep; 43(1):19-25. PubMed ID: 8917631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
    Tang CK; Concepcion XZ; Milan M; Gong X; Montgomery E; Lippman ME
    Cancer Res; 1999 Oct; 59(20):5315-22. PubMed ID: 10537315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heregulins and the ErbB-2/3/4 receptors in gliomas.
    Westphal M; Meima L; Szonyi E; Lofgren J; Meissner H; Hamel W; Nikolics K; Sliwkowski MX
    J Neurooncol; 1997 Dec; 35(3):335-46. PubMed ID: 9440030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance.
    Lupu R; Cardillo M; Harris L; Hijazi M; Rosenberg K
    Semin Cancer Biol; 1995 Jun; 6(3):135-45. PubMed ID: 7495981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.
    Liu Y; el-Ashry D; Chen D; Ding IY; Kern FG
    Breast Cancer Res Treat; 1995 May; 34(2):97-117. PubMed ID: 7647336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry.
    Esteva FJ; Hortobagyi GN; Sahin AA; Smith TL; Chin DM; Liang SY; Pusztai L; Buzdar AU; Bacus SS
    Pathol Oncol Res; 2001; 7(3):171-7. PubMed ID: 11692142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
    Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
    Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
    Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
    Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
    Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.